Nuwellis gets FDA clearance for an additional specialty dELC

Nuwellis announced it has received U.S. Food and Drug Administration FDA clearance for its specialty peripheral dual lumen extended length catheter or dELC. The addition of a new 12 cm catheter provides clinicians who treat patients with fluid overload with an additional venous access option to use the company’s Aquadex ultrafiltration system. “Expanding peripheral venous access options through our dELC comes at an important time, as healthcare providers work to bring ultrafiltration therapy to patients within ICU and stepdown units,” said Nestor Jaramillo, Jr., President and Chief Executive Officer of Nuwellis. “Our unwavering commitment is to make Aquadex safe, effective, and easy to administer to the countless patients suffering from fluid overload, because of heart failure or critical illnesses, in our healthcare systems.”